Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease

Journal of Receptors and Signal Transduction

Volumn 28, Issue 4, 2008, Pages 375-401

  Hernández, Ciria C ^a,b   Nascimento, José H ^a   Chaves, Elen A ^a   Costa, Patrícia C ^a   Masuda, Masako O ^a   Kurtenbach, Eleonora ^a   Campos De Carvalho, Antônio C ^a   Giménez, Luis E ^a,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Acetylcholine; Allosteric binding site; Autoantibody; Chagas' disease; Gallamine; M2 muscarinic acetylcholine receptor; N methyl scopolamine; W84

Indexed keywords

ACETYLCHOLINE; AUTOANTIBODY; GALLAMINE; IMMUNOGLOBULIN G ANTIBODY; METHYLSCOPOLAMINE; MUSCARINIC RECEPTOR; PEPTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD DONOR; BRADYCARDIA; CHAGAS DISEASE; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; FEMALE; HEART RATE; HUMAN; ISOLATED HEART; LIGAND BINDING; NONHUMAN; PROTEIN PURIFICATION; RADIOASSAY; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ACETYLCHOLINE; ALLOSTERIC SITE; ANIMALS; AUTOANTIBODIES; CHAGAS DISEASE; CHOLINERGIC AGENTS; GALLAMINE TRIETHIODIDE; HEART; HEART RATE; HUMANS; LIGANDS; MYOCARDIUM; NEUROMUSCULAR NONDEPOLARIZING AGENTS; NICOTINIC ANTAGONISTS; RABBITS; RECEPTOR, MUSCARINIC M2; SWINE;

EID: 49649105574     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890802262319     Document Type: Article

References (54)

1. Schmunis GA. American Tripanosomiasis as a public health problem. In: Chagas' Disease and the Nervous System, Scientific publication 547. Washington, DC, Pan-American Health Organization, 1994, 3-31.
2. Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy: Microbiological and molecular biological aspects. Cardiovasc Res 2003, 60, 11-25.
3. Mason JW. Myocarditis and dilated cardiomyopathy: An inflammatory link. Cardiovasc Res 2003, 60, 5-10.
4. Chiale PA, Ferrari I, Mahler E, Vallazza MA, Elizari MV, Rosenbaum MB, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001, 103, 1765-1771.
5. Matsui S, Fu ML. Myocardial injury due to G-protein coupled receptor-autoimmunity. Jpn Heart J 1998, 39, 261-274.
6. Kierszenbaum F. Views on the autoimmunity hypothesis for Chagas disease pathogenesis. FEMS Immunol Med Microbiol 2003, 37, 1-11.
7. 1 adrenergic receptor coding plasmids impair cardiac function in mice. J Mol Cell Cardiol 2005, 38, 703-714.
8. 2+ currents. Cardiovasc Res 2003, 58, 55-65.
9. Elies R, Ferrari I, Wallukat G, Lebesgue D, Chiale P, Elizari M, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J Immunol 1996, 157, 4203-4211.
10. Ferrari I, Levin MJ, Wallukat G, Elies R, Lebesgue D, Chiale P, et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 1995, 182, 59-65.
11. Christopoulos A, Lanzafame A, Mitchelson F. Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 1998, 25, 185-194.
12. Leppik RA, Miller RC, Eck M, Paquet JL. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol Pharmacol 1994, 45, 983-990.
13. Lazareno S, Birdsall NJ. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 1995, 48, 362-378.
14. Trankle C, Mohr K. Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors. Mol Pharmacol 1997, 51, 674-682.
15. Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, Gonzalez R, et al. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int J Cardiol 1985, 8, 45-56.
16. de Oliveira SF, Pedrosa RC, Nascimento JH, Campos de Carvalho AC, Masuda MO. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. Circulation 1997, 96, 2031-2037.
17. Costa PC, Fortes FS, Machado AB, Almeida NA, Olivares EL, Cabral PR, et al. Sera from chronic chagasic patients depress cardiac electrogenesis and conduction. Braz J Med Biol Res 2000, 33, 439-446.
18. World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 2001, 79, 373-374.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193, 265-275.
20. World Medical Association, American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol 2002, 283, R281-283.
21. Lazareno S, Birdsall N. Measurement of competitive and allosteric interactions in radioligand binding studies. In G Protein-Coupled Receptors, edited by Haga T, Berstein G. Boca Raton, CRC Press, 1999, 1-48.
22. Lew MJ, Angus JA. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 1995, 16, 328-337.
23. Clark AL, Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 1976, 58, 323-331.
24. Lee NH, el-Fakahany EE. Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem Pharmacol 1991, 42, 199-205.
25. Ellis J, Huyler J, Brann MR. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 1991, 42, 1927-1932.
26. Trankle C, Kostenis E, Burgmer U, Mohr K. Search for lead structures to develop new allosteric modulators of muscarinic receptors. J Pharmacol Exp Ther 1996, 279, 926-933.
27. 2 receptors. Naunyn Schmiedebergs Arch Pharmacol 1998, 357, 363-370.
28. Goin JC, Borda E, Leiros CP, Storino R, Sterin-Borda L. Identification of antibodies with muscarinic cholinergic activity in human Chagas' disease: pathological implications. J Auton Nerv Syst 1994, 47, 45-52.
29. Goin JC, Leiros CP, Borda E, Sterin-Borda L. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: Functional and pathological implications. FASEB J 1997, 11, 77-83.
30. Masuda MO, Levin M, De Oliveira SF, Dos Santos Costa PC, Bergami PL, Dos Santos Almeida NA, et al. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998, 12, 1551-1558.
31. Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the betaand muscarinic receptors in cardiomyopathy. Herz 2000, 25, 261-266.
32. Goin JC, Borda ES, Auger S, Storino R, Sterin-Borda L. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: Association with bradycardia. Heart 1999, 82, 273-278.
33. Sterin-Borda L, Joensen L, Bayo-Hanza C, Esteva M, Borda E. Therapeutic use of muscarinic acetylcholine receptor peptide to prevent mice chagasic cardiac dysfunction. J Mol Cell Cardiol 2002, 34, 1645-1654.
34. Sterin-Borda L, Gorelik G, Borda ES. Chagasic IgG binding with cardiac muscarinic cholinergic receptors modifies cholinergic-mediated cellular transmembrane signals. Clin Immunol Immunopathol 1991, 61, 387-397.
35. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000, 21, 90-113.
36. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of Gprotein-coupled receptors: Similarities to rhodopsin. Biochemistry 2003, 42, 2759-2767.
37. Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 1989, 36, 840-847.
38. Page KM, Curtis CA, Jones PG, Hulme EC. The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. Eur J Pharmacol 1995, 289, 429-437.
39. Hulme EC, Lu ZL, Saldanha JW, Bee MS. Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 2003, 31, 29-34.
40. Vogel WK, Sheehan DM, Schimerlik MI. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: The significance of Tyr403 in the binding of agonists and functional coupling. Mol Pharmacol 1997, 52, 1087-1094.
41. Stockton JM, Birdsall NJ, Burgen AS, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983, 23, 551-557.
42. Proska J, Tucek S. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol Pharmacol 1994, 45, 709-717.
43. Krejci A, Tucek S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol Pharmacol 2001, 60, 761-767.
44. 2 acetylcholine receptor. Eur J Biochem 1998, 251, 659-666.
45. Ellis J, Seidenberg M. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 1992, 42, 638-641.
46. 2 receptors. J Pharmacol Exp Ther 1997, 282, 278-285.
47. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002, 54, 323-374.
48. Birdsall NJ, Lazareno S, Popham A, Saldanha J. Multiple allosteric sites on muscarinic receptors. Life Sci 2001, 68, 2517-2524.
49. May LT, Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 2003, 3, 551-556.
50. Maass A, Kostenis E, Mohr K. Potentiation by alcuronium of the antimuscarinic effect of N-methylscopolamine in guinea pig left atria. Eur J Pharmacol 1995, 272, 103-106.
51. Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, Sugimoto M. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mol Pharmacol 1999, 55, 778-786.
52. Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, et al. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Sci 1997, 60, 1047-1052.
53. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997, 52, 172-179.
54. Matsui S, Fu ML, Hayase M, Katsuda S, Yamaguchi N, Teraoka K, et al. Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol 2001, 38, S43-49.